10 steps to secure investment as a life science scale up

Yogan Patel.png

Unlocking the potential of your groundbreaking life science business begins with securing the funding needed to propel your innovation to new heights. 

In this comprehensive guide, Yogan Patel, Partner, and Head of Life Sciences at MHA, unveils a ten-step roadmap for preparing to pitch for funding. Each step represents a critical milestone on your journey towards acquiring the financial resources that will enable you to drive innovation, make a positive impact on healthcare, and transform your vision into a thriving reality.

Whether you're a biotech startup on the cusp of a medical breakthrough or a molecular diagnostics company looking to expand your operations, the path to funding success demands careful planning and precise execution. From refining your value proposition and developing a compelling narrative that resonates with potential investors to conducting rigorous market research and assembling a rock-solid financial plan, this infographic equips you with the knowledge and strategies needed to make your pitch stand out in a crowded funding landscape.

The life science sector is known for its unique challenges, and this roadmap is designed to help you navigate them with confidence and precision.

10 essential steps for building investor-ready documents

Biotech funding: 10 steps to secure investment as a life science scale up

Market Research

Your research is likely to have been leading edge and the result of years of collective work between you and your fellow researchers. It is essential that you can showcase the potential of your work with evidence led approach that ideally will already have included some peer assessment, notwithstanding the need to protect your IP.

Business plan

Prepare a comprehensive business plan that outlines your vision, mission, target market, competitive analysis, marketing strategy and financial projections. Investors will want to see that you have a clear plan for commercialisation. This is possibly the toughest stage as comparative metrics may be difficult to build, attempt to breakdown the market and segment it by example using geography, patient type/outcome and the cost of existing therapies as a benchmark.

Investment proposal/Pitch Deck

Create a compelling investment proposal or pitch deck that presents you and your team as a strong proposition. This needs to be in a concise and professionally produced format; detailed information should be on hand but not in the slide deck or it becomes difficult to track in the context of a pitch presentation. Include key highlights about your therapy, the problem it addresses, how it works, clinical trial results (if any), your business model including matters such as outsourcing and manufacturing if appropriate, revenue projections and the amount of investment you are seeking.

Regulatory and clinical trial documentation

Your product could be facing stringent regulatory requirements. Prepare documentation related to the regulatory approvals you have obtained or are pursuing. If you have already conducted pre-clinical trials, include relevant data and results to demonstrate safety and efficacy.

Intellectual Property (IP)

Perhaps this is an obvious point, but investors will want to know about the intellectual property protecting your therapy or technology. Provide information on patents and any other forms of IP you have secured or have pending. If you don’t have this, be prepared to demonstrate how this will be managed with expert opinions to support your points.

Team and advisory support

You and your team are a big part of the investment, after all, there is likely to be no revenue, so it’s down to you, your team, and the IP. Highlight the expertise of your management team and key personnel involved in the project to date. Investors will want to know that you have a capable and experienced team to drive the business forward. Ideally, you will already have advisors or the equivalent in the form of non-executives with appropriate sector expertise, you can mention their involvement as a form of endorsement. You may also wish to include other advisors including accountants and lawyers who may have supported the development of your business or pitch.

Financial plan

You will need detailed financial statements and plans for your business, including profit and loss statements, balance sheets and cash flow statements. You will also need to take a medium-term view on how you see the business developing, so present your financial projections for the next 3-5 years, showing how the investment should be uitilised and the potential return on investment.

Managing risks

Be transparent about the risks involved in your business and IP; to some extent you may be navigating uncharted waters given that you are likely breaking new ground and research. Discuss how you might plan to mitigate the risks, whether these are around the product, key staff or the market and customers. Investors appreciate a thorough understanding of the potential challenges and how you plan to navigate them as this gives them the opportunity to structure their investment or indeed introduce new co-investment partners.

Securing regulatory approval and payment

Depending on where you intend to market your product or therapy, you will need to think about your plans for regulatory approval and how you intend to secure reimbursement once the product or therapy is on the market. Investors will want to see that you have quantified the cost of treatment where appropriate and that it is likely to secure approval from the prevailing regulatory authority.

Market engagement

Give some consideration to your business development strategy and the balance of marketing and sales activity. You will need to articulate your strategy for reaching your target market and building a customer base. It will also be essential to demonstrate how you intend managing the ‘mark access’ process of engaging with physicians, patients, and key opinion leaders; whether you budget for this in-house or outsource it, you will need to be clear on the resources for this and timelines.


More news and updates 

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.


More within